Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) Income towards Parent Company: 2019-2024

Historic Income towards Parent Company for Lyell Immunopharma (LYEL) over the last 6 years, with Dec 2024 value amounting to -$334.7 million.

  • Lyell Immunopharma's Income towards Parent Company rose 23.69% to -$34.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$327.6 million, marking a year-over-year decrease of 71.61%. This contributed to the annual value of -$334.7 million for FY2024, which is 49.71% down from last year.
  • As of FY2024, Lyell Immunopharma's Income towards Parent Company stood at -$334.7 million, which was down 49.71% from -$223.6 million recorded in FY2023.
  • Lyell Immunopharma's 5-year Income towards Parent Company high stood at -$180.0 million for FY2022, and its period low was -$334.7 million during FY2024.
  • Its 3-year average for Income towards Parent Company is -$246.1 million, with a median of -$223.6 million in 2023.
  • As far as peak fluctuations go, Lyell Immunopharma's Income towards Parent Company plummeted by 119.22% in 2020, and later increased by 15.73% in 2022.
  • Over the past 5 years, Lyell Immunopharma's Income towards Parent Company (Yearly) stood at -$206.0 million in 2020, then decreased by 3.70% to -$213.6 million in 2021, then increased by 15.73% to -$180.0 million in 2022, then fell by 24.19% to -$223.6 million in 2023, then slumped by 49.71% to -$334.7 million in 2024.